NCT04938804 is a NA clinical trial of Low-dose computed tomography in Lung Cancer, sponsored by The First Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT04938804?

NCT04938804 is sponsored by The First Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT04938804?

Interventions in NCT04938804: Low-dose computed tomography.

What condition does NCT04938804 study?

NCT04938804 studies Lung Cancer.

Is NCT04938804 still recruiting?

NCT04938804 is currently recruiting now. Last updated 9 January 2024.

Last reviewed 2024-01-09 · How we verify

NCT04938804

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-risk Based Lang Cancer Screening With a One-off LDCT

Recruiting now NA Last updated 9 January 2024

What this trial tests

NA trial testing Low-dose computed tomography in Lung Cancer in 11,000 participants. Currently enrolling.

Timeline

12 December 2015

Primary endpoint
1 December 2025

1 December 2026

Quick facts

Lead sponsor	The First Affiliated Hospital of Guangzhou Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	11,000
Start date	12 December 2015
Primary completion	1 December 2025
Estimated completion	1 December 2026
Sites	1 location across China

Drugs / interventions tested

Low-dose computed tomography

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Who can join

Adults 40 to 74, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Guangzhou Lung-Care Project is a single-arm, prospective cohort study using one-time low-dose computed tomography for the early detection of LC, recruiting residents aged 40-74 years from four communities in Guangzhou between 2015 and 2021.The primary outcome was LC detection rate in eligible participants without restrictions based on high-risk factors and the proportion of stage I LC cases, and to investigate the various factors associated with the development of LC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in lung cancer screening and early detection.
Li C, Wang H, Jiang Y, Fu W, et al · · 2022 · cited 61× · PMID 35535966 · DOI 10.20892/j.issn.2095-3941.2021.0690
Diameter thresholds for pure ground-glass pulmonary nodules at low-dose CT screening: Chinese experience.
Ye W, Fu W, Li C, Li J, et al · · 2025 · cited 4× · PMID 39689940 · DOI 10.1136/thorax-2024-221642

Verify or expand the search:

Other trials of Low-dose computed tomography

Trials testing the same drug.

NCT04217655 — Low-dose Computed Tomography-guided Core Needle Biopsy for Lung Nodules · NA · completed

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other The First Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04938804 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
Last refreshed: 9 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04938804.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing